
Douglas L Jennings

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/265026/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Assessment of long-term anticoagulation in patients with a continuous-flow left-ventricular assist device: A pilot study. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, e1-e2.	0.8	69
2	Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. American Journal of Transplantation, 2022, 22, 2083-2088.	4.7	64
3	Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants. American Journal of Transplantation, 2022, 22, 1925-1926.	4.7	54
4	Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 1226-1233.	0.6	42
5	Clinical Outcomes Associated With Chronic Antimicrobial Suppression Therapy in Patients With Continuousâ€Flow Left Ventricular Assist Devices. Artificial Organs, 2014, 38, 875-879.	1.9	41
6	Inhaled Pulmonary Vasodilator Therapy for Management of Right Ventricular Dysfunction after Left Ventricular Assist Device Placement and Cardiac Transplantation. Pharmacotherapy, 2017, 37, 944-955.	2.6	35
7	COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era. American Journal of Transplantation, 2022, 22, 2682-2688.	4.7	35
8	Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis. International Journal of Cardiology, 2018, 265, 71-76.	1.7	32
9	Survey of Anticoagulation Practices with the Impella Percutaneous Ventricular Assist Device at High-Volume Centers. Journal of Interventional Cardiology, 2019, 2019, 1-6.	1.2	30
10	Pharmacotherapeutic Management of Gastrointestinal Bleeding in Patients with Continuousâ€Flow Left Ventricular Assist Devices. Pharmacotherapy, 2017, 37, 1432-1448.	2.6	29
11	Metaâ€Analysis of Time in Therapeutic Range in Continuousâ€Flow Left Ventricular Assist Device Patients Receiving Warfarin. Artificial Organs, 2018, 42, 700-704.	1.9	29
12	Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. American Journal of Transplantation, 2020, 20, 3620-3630.	4.7	27
13	Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support. Pharmacotherapy, 2017, 37, 1272-1283.	2.6	26
14	Optimizing anticoagulation for patients receiving Impella support. Pharmacotherapy, 2021, 41, 932-942.	2.6	22
15	Effective Anticoagulation for a Percutaneous Ventricular Assist Device Using a Heparin-Based Purge Solution. Annals of Pharmacotherapy, 2013, 47, 1364-1367.	1.9	20
16	Safety of Anticoagulation Reversal in Patients Supported with Continuous-Flow Left Ventricular Assist Devices. ASAIO Journal, 2014, 60, 381-384.	1.6	18
17	Gut microbial diversity, inflammation, and oxidative stress are associated with tacrolimus dosing requirements early after heart transplantation. PLoS ONE, 2020, 15, e0233646.	2.5	15
18	Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients. Heart Failure Reviews, 2015, 20, 573-578.	3.9	14

DOUGLAS L JENNINGS

#	Article	IF	CITATIONS
19	A multidisciplinary team-based process improves outpatient anticoagulation quality with continuous-flow left-ventricular assist devices. International Journal of Cardiology, 2016, 218, 118-119.	1.7	14
20	SARSâ€CoVâ€⊋ infection increases tacrolimus concentrations in solidâ€organ transplant recipients. Clinical Transplantation, 2021, 35, e14193.	1.6	14
21	Management of primary graft failure after heart transplantation: Preoperative risks, perioperative events, and postoperative decisions. Clinical Transplantation, 2019, 33, e13557.	1.6	13
22	Device-Related Thrombosis in Continuous-Flow Left Ventricular Assist Device Support. Journal of Pharmacy Practice, 2016, 29, 58-66.	1.0	12
23	Clinical outcomes of older adults listed for heart transplantation in the <scp>United States</scp> . Journal of the American Geriatrics Society, 2021, 69, 2507-2517.	2.6	12
24	Pre-cardiac transplant amiodarone use is not associated with postoperative mortality: An updated meta-analysis. International Journal of Cardiology, 2017, 236, 345-347.	1.7	11
25	Nitazoxanide treatment for norovirus infection in solid organ transplant recipients. Clinical Transplantation, 2022, 36, e14594.	1.6	11
26	Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction. Clinical Transplantation, 2020, 34, e13779.	1.6	9
27	PCSK9 Inhibitor Use in Heart Transplant Recipients: A Case Series and Review of the Literature. Transplantation, 2020, 104, e38-e39.	1.0	9
28	Impact of heart failure drug therapy on rates of gastrointestinal bleeding in LVAD recipients: An INTERMACS analysis. International Journal of Artificial Organs, 2021, 44, 965-971.	1.4	8
29	Dosing of Vancomycin in Patients with Continuous-Flow Left Ventricular Assist Devices: A Clinical Pharmacokinetic Analysis. International Journal of Artificial Organs, 2014, 37, 270-274.	1.4	7
30	Use of cangrelor during venoarterial extracorporeal membrane oxygenation following percutaneous coronary intervention. Artificial Organs, 2020, 44, 339-340.	1.9	7
31	Immunosuppression considerations in simultaneous organ transplant. Pharmacotherapy, 2021, 41, 59-76.	2.6	7
32	Abciximab/Heparin Therapy for Left Ventricular Assist Device Implantation in Patients With Heparin-Induced Thrombocytopenia. Annals of Thoracic Surgery, 2018, 105, 122-128.	1.3	6
33	Methylene Blue Does Not Improve Vasoplegia After Left Ventricular Assist Device Implantation. Annals of Thoracic Surgery, 2021, 111, 800-808.	1.3	6
34	Pharmacotherapy for durable left ventricular assist devices. Pharmacotherapy, 2021, 41, 14-27.	2.6	6
35	Less bleeding associated with apixaban versus other direct acting oral anticoagulation in solid organ transplant recipients. Clinical Transplantation, 2021, 35, .	1.6	6
36	A reappraisal of the pharmacologic management of gastrointestinal bleeding in patients with continuous flow left ventricular assist devices. Heart Failure Reviews, 2021, 26, 277-288.	3.9	5

Douglas L Jennings

#	Article	IF	CITATIONS
37	Pre–Cardiac Transplant Amiodarone Use Increases Postoperative Mortality. Annals of Pharmacotherapy, 2016, 50, 514-515.	1.9	4
38	Red Cell Distribution Width Predicts 90 Day Mortality in Continuous-Flow Left Ventricular Assist Device Patients. ASAIO Journal, 2019, 65, 233-240.	1.6	4
39	Prior Amiodarone Exposure Reduces Tacrolimus Dosing Requirements in Heart Transplant Recipients. Progress in Transplantation, 2019, 29, 129-134.	0.7	4
40	Impact of Platelet Functional Assays on the Cost of Treating Suspected Heparin-Induced Thrombocytopenia. Journal of Pharmacy Practice, 2015, 28, 398-403.	1.0	3
41	PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis. Heart Failure Reviews, 2023, 28, 149-156.	3.9	3
42	Relationship of hemolysis with discordance in paired activated partial thromboplastin time and anti-Factor Xa measurements in continuous-flow left ventricular assist device patients. Journal of Heart and Lung Transplantation, 2016, 35, 1365-1367.	0.6	2
43	Angiotensin receptor neprilysin inhibitor use in patients with left ventricular assist devices: A single-center experience. International Journal of Artificial Organs, 2022, 45, 118-120.	1.4	2
44	Increase in short-term of rejection in heart transplant patients receiving granulocyte colony-stimulating factor. Journal of Heart and Lung Transplantation, 2018, 37, 1475.	0.6	1
45	Preâ€ŧransplant amiodarone use does not affect longâ€ŧerm heart transplant survival. Pharmacotherapy, 2021, , .	2.6	1
46	Chronic intermittent intravenous immunoglobulin in heart transplant recipients with elevated donorâ€specific antibody levels. Clinical Transplantation, 2021, , e14524.	1.6	1
47	Clinical Outcomes with Beta-blockers after Myocardial Infarction: Finding the Right Patient and the Right Regimen. American Journal of Medicine, 2014, 127, e17.	1.5	0
48	Reply. Annals of Thoracic Surgery, 2018, 106, 309-310.	1.3	0
49	Mammalian Target of Rapamycin Inhibitors and Survival in Heart Transplant Recipients. Journal of the American College of Cardiology, 2018, 71, 2859-2860.	2.8	0
50	Engineering a Brighter Future: The Evolving Role of the Pharmacist in the Era of the HeartMate 3. Annals of Pharmacotherapy, 2019, 53, 430-433.	1.9	0